



FOR IMMEDIATE RELEASE: 08/29/2022

Contact information:

Press Room

Ora Biomedical, Inc.

press@orabiomedical.com

YouTube: [Ora Biomedical, Inc.](#)

Twitter: [@OraBiomedical](#)

Ora Biomedical Announces Optispan Ventures as Lead Investor in Pre-Seed Investment Round

Seattle, WA – Ora Biomedical, Inc., a new pharmaceutical company that develops healthy aging therapeutics, announced an investment deal with Optispan Ventures which includes financing and research headquarters to build a high-throughput longevity drug discovery facility in the Pacific Northwest.

Ora Biomedical Inc. performs massively large-scale drug discovery using robotics coupled with machine learning AI to identify novel preclinical longevity therapeutics. Validation studies are then performed to further develop the best candidates for extending lifespan and preventing age-related diseases in humans and companion animals.

Ora Biomedical's proprietary drug discovery platform, the WormBot-AI, was developed by scientists in Dr. Matt Kaeberlein's lab at the University of Washington School of Medicine. Ora Biomedical holds the exclusive, worldwide commercial use rights to the WormBot-AI technology.

Optispan Ventures is focused on healthspan innovations that will define 21st Century Medicine. "Interventions that target the biology of aging have the potential to dramatically improve quality of life by increasing healthspan - a healthy, disease-free lifespan is the goal. We are pleased to partner with Ora to apply their game-changing Wormbot-AI technology and go far beyond what has previously been possible in this field", says Stuart McKee, CEO of Optispan.

With capital financing and location space from Optispan Ventures, Ora Biomedical will build a scalable WormBot-AI drug discovery factory capable of performing more than 300,000 lifespan experiments per year. This is a game changer - currently, ***it is estimated that fewer than 5,000 such experiments are performed annually worldwide.***

"Optispan Ventures and Ora Biomedical have a shared vision of revolutionizing how we age" says Ora Biomedical CEO, Dr. Mitchell Lee. "Thanks to our partnership with Optispan, we can accelerate the launch of our longevity drug discovery factory and move one step closer to developing breakthrough healthy aging therapeutics for humans and all other animals we love."

About Ora Biomedical, Inc.: Ora Biomedical, Inc. is a longevity biotechnology pharmaceutical company based in Seattle, WA. Founded in 2022, Ora Biomedical develops small molecule therapeutics that extend lifespan and delay chronic illness by targeting the underlying molecular mechanisms of aging. Ora Biomedical performs massively high-throughput drug screening to identify gerotherapeutics using the WormBot-AI, an automated high-throughput robotics platform combined with state-of-the-art AI-based data analysis. <https://orabiomedical.com/>

Ora Biomedical

About Optispan Ventures: Optispan Ventures is a collection of companies focused on the idea that our current disease care system needs an upgrade. We are relentlessly pursuing innovations that will change the way we think about aging and disease. We are committed to science and fact-based discovery that will bring optimal health spans to everyone. www.optispan.life

###